Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eight-week double-blind placebo-controlled multicenter study of SR58611A in elderly patients with major depressive disorder
2005-005597-67Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing SR58611A 350 mg q12h with Placebo (2 arms). Primary endpoint: Efficacy on depressive symptoms. Started Feb 2006; status: completed.
02
Drugs
amibegron
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2005-005597-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005597-67.